Schütz N, Märker-Hermann E
Klinik Innere Medizin IV (Rheumatologie, klinische Immunologie und Nephrologie), HSK, Dr.-Horst-Schmidt-Kliniken GmbH, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Deutschland.
Z Rheumatol. 2012 Jan;71(1):78-82. doi: 10.1007/s00393-011-0931-2.
Multiple myeloma (MM) is a disease of the elderly with an incidence of 4/100,000 per year and can occur as a comorbidity especially in elderly patients with rheumatoid arthritis (RA). For MM and also for RA interleukin-6 (IL-6) is a pathogenetically important cytokine in both disease events. This article presents the case of a female patient who achieved sustained remission of RA and stabilization of MM with quantitative reduction of paraprotein by treatment with tocilizumab. The question whether tocilizumab represents a meaningful treatment approach for treatment of RA when MM is also present will be discussed.
多发性骨髓瘤（MM）是一种老年疾病，年发病率为十万分之四，可作为合并症出现，尤其是在患有类风湿关节炎（RA）的老年患者中。对于MM以及RA而言，白细胞介素-6（IL-6）在这两种疾病过程中都是具有致病重要性的细胞因子。本文介绍了一名女性患者的病例，该患者通过使用托珠单抗治疗，实现了RA的持续缓解以及MM的病情稳定，副蛋白定量减少。本文将讨论当患者同时患有MM时，托珠单抗是否是治疗RA的一种有效治疗方法这一问题。
